Compare GoPro Inc (GPRO) vs Heron Therapeutics Inc (HRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GoPro Inc vs Heron Therapeutics Inc — how do they compare? GoPro Inc trades at $1.19 (market cap $243.50M), while Heron Therapeutics Inc trades at $0.37 (market cap $68.01M). The key difference: GoPro Inc is far larger — about 3.6× Heron Therapeutics Inc's market cap, and GoPro Inc is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold GoPro Inc for 45 Days and Heron Therapeutics Inc for 35 Days on average.
| GPRO | HRTX | |
|---|---|---|
Market Cap | $243.50M | $68.01M |
Volume | 11,527,160 | 1,891,941 |
Sector | Technology | Health |
52-Week High | $2.35 | $1.49 |
52-Week Low | $0.58 | $0.27 |
Typical Hold Time | 45 Days | 35 Days |
Enterprise Value | $302.28M | $174.75M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GoPro (GPRO) trades at $1.22, down 7.58% on the day, amid volatile trading following a recent surge driven by merger news and influencer investment. The stock shows bullish technical signals with oversold RSI conditions, but fundamentals remain weak with declining revenues and persistent net losses. Recent developments include a proposed $285 million merger with Starman Optical and significant stake acquisition by YouTube creator Markiplier, creating both opportunity and uncertainty for shareholders.
The outlook remains highly speculative with the merger offering potential upside but facing shareholder litigation over valuation concerns. Key risks include continued operational losses, competitive pressures from smartphones, and merger execution challenges. Analyst sentiment is mixed with only 21% buy ratings, reflecting skepticism about the company's standalone prospects versus merger-driven speculation.
HRTX trades at $0.39, up 17.58% today, with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7 million but missed EPS estimates with a $0.03 loss. Despite negative profitability metrics, analyst consensus remains strongly positive with 89% buy ratings. Recent news highlights ongoing comparisons with peers and earnings performance discussions.
The outlook is mixed: strong analyst support and technical momentum suggest potential upside, but persistent losses and high valuation ratios pose significant risks. Investment opportunity hinges on revenue growth translating to profitability, while key risks include execution challenges and competitive pressures in the biotechnology sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About GoPro Inc
GoPro Inc is a United States-based company that is principally engaged in designing and providing cameras, mounts, drones and appliances. The company outsources a part of manufacturing to third parties in China. The company sells products across the world through its direct sales channel, which generates over half of total revenue, and indirectly through its distribution channel. The company has presence, including in the Americas, Europe, Middle East, Africa, and Asia-Pacific, with the Americas contributing over half of total revenue.
Read more on GPRO →About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →
